Newsroom
Sorted by: Latest
-
A Premier Jumping League (PJL) e a McCarthy Jumping Team anunciam aquisição histórica
NOVA YORK--(BUSINESS WIRE)--A Premier Jumping League (PJL) anunciou hoje que o experiente corretor, investidor e piloto de corridas Jason McCarthy e a McCarthy Jumping League LLC adquiriram a primeira equipe da PJL em uma aquisição histórica de US$ 50 milhões, aproveitando o impulso crescente da aclamada liga profissional de salto a cavalo. Esse investimento marcante representa uma avaliação sem precedentes para uma equipe em uma competição esportiva recém-criada e ressalta a confiança que inve...
-
HAFNIA LIMITED: Hafnia Announces Planned CEO Succession
SINGAPORE--(BUSINESS WIRE)--Hafnia Limited (“Hafnia”, the “Company”, OSE ticker code: “HAFNI”, NYSE ticker code: “HAFN”) announces today that Mikael Skov has decided to step down as Chief Executive Officer (CEO) of Hafnia effective 1 September 2026. The Board of Directors has appointed Søren Steenberg Jensen, EVP, Head of Asset Management to succeed Mikael as CEO. Mikael Skov has led Hafnia since its establishment in 2010 and has played a defining role in building the Company into one of the wo...
-
In Line With the LEAP | 28 Portfolio Rotation Strategy, Bureau Veritas Signs an Agreement to Sell Its Oil & Petrochemicals and Coal Testing and Inspection Business
COURBEVOIE, France--(BUSINESS WIRE)--Bureau Veritas, a global leader in Testing, Inspection, and Certification services (TIC), announces that it has entered exclusive negotiations with Triton Partners regarding the sale of its Oil & Petrochemicals and Coal testing and inspection business. This strategic divestment is in full alignment with the Group’s LEAP | 28 strategy. The proposed transaction would include the Oil & Petrochemicals and Coal testing and inspection activities. In 2025,...
-
Conformément à sa stratégie de rotation du portefeuille LEAP | 28, Bureau Veritas signe un accord en vue de céder ses activités d’essais et d’inspection de Produits Pétroliers & Pétrochimiques et Charbon
COURBEVOIE, France--(BUSINESS WIRE)--Bureau Veritas, un leader mondial des services de Test, Inspection et Certification (TIC), annonce être entré en négociations exclusives avec Triton Partners en vue de la cession de ses activités d’essais et d’inspection de Produits Pétroliers & Pétrochimiques et Charbon. Cette cession stratégique s’inscrit pleinement dans la stratégie LEAP | 28 du Groupe. La transaction envisagée porterait sur les activités d’essais et d’inspection de Produits Pétrolier...
-
Corient accélère sa croissance européenne avec l’acquisition de Letus Private Office
MIAMI et PARIS--(BUSINESS WIRE)--Corient a annoncé aujourd’hui un accord portant sur l’acquisition de Letus Private Office (« Letus »), un multi-family office indépendant et cabinet de conseil en gestion de fortune au service d’entrepreneurs et de familles fortunées en France et en Europe. L’acquisition, sujette à finalisation, capitalise sur les transactions récentes qui ont fait de Corient le plus grand multi-family office et gestionnaire de fortune non bancaire au monde, focalisé sur la clie...
-
Corient Accelerates European Growth With the Addition of Letus Private Office
MIAMI & PARIS--(BUSINESS WIRE)--Corient acquires Letus Private Office, a wealth advisory firm serving ultra-high-net-worth individuals and families across France and Europe....
-
FDA Grants Priority Review To Genentech’s Application for Enspryng, the First and Only At-Home Subcutaneous Treatment Option for Thyroid Eye Disease (TED)
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted and granted priority review to a supplemental Biologics License Application (sBLA) for Enspryng® (satralizumab) for the treatment of thyroid eye disease (TED). The filing acceptance is based on results from the two randomized, placebo-controlled global Phase III SatraGO studies assessing the safety and ef...
-
Hengrui’s Heng Yi® Approved in China as an Innovative Cyclosporine Ophthalmic Solution for the Treatment of Dry Eye Disease
SHANGHAI & HEIDELBERG, Germany & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Hengrui Pharma, a global pharmaceutical company focused on scientific and technological innovation, and Novaliq GmbH (“Novaliq”), a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on its unique EyeSol® water-free platform technology, announce today that on June 23, 2026, the China National Medical Products Administration (NMPA) has approved Heng Yi® (0.1% cyclosporine ophthalmic solution...
-
Ungoverned AI Agents and Sophisticated Deepfakes Pose Critical Threats for the UAE & Saudi Arabia Organisations, New KnowBe4 Research Warns
DUBAI, United Arab Emirates--(BUSINESS WIRE)--KnowBe4, the global leader in digital workforce security, securing both AI agents and humans, today announced the launch of its new research report, "From Agentic Risk to Human Wins: Building a Culture of Security in the Era of Agentic AI." The findings expose a dangerous reality for modern organisations in the United Arab Emirates and Saudi Arabia: autonomous AI tools are expanding the corporate attack surface faster than security teams can impleme...
-
「ぼっち・ざ・ろっく!」青春コンプレックス 6月20日(土)公開スタート!
東京--(BUSINESS WIRE)--(ビジネスワイヤ) -- 東京都は、東京の夜を彩る新たな観光資源創出に向け、都庁舎をキャンバスに光と音で多彩なアートを表現するプロジェクションマッピングを通年上映しています。 このたび、国内外で高い人気を集めているアニメ「ぼっち・ざ・ろっく!」をモチーフとした新作品『「ぼっち・ざ・ろっく!」青春コンプレックス』 の初回上映を6月20日(土)に行いました。今後年間を通じて、平日及び土日のコンテンツとして上映いたします。 2024年2月に開始した本取組は国内外から多くのご来場をいただき、累計観覧者が140万人を突破いたしました。 東京の新たな観光名所として、高い芸術性や世界をリードする技術・コンテンツ等によって生み出される本取組に、引き続きご注目ください。 新作品『「ぼっち・ざ・ろっく!」青春コンプレックス』公開初日の様子 公開初週の土日は約5,500人が観覧 『「ぼっち・ざ・ろっく!」青春コンプレックス』公開初週の土日は雨が降る場面があったにも関わらず、国内外の観光客や家族連れなど約5,500人が都民広場を訪れました。 訪れた方からは『あの「青...